Skip to content

Pre-sleep treatment with galantamine stimulates lucid dreaming: A double-blind, placebo-controlled, crossover study

Stephen LaBerge, Kristen Lamarca, Benjamin Baird

PLoS One August 8, 2018 DOI: 10.1371/journal.pone.0201246 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized crossover trial Placebo-controlled Double-blind Peer reviewed
Sample size 121
Population Adults with high dream recall and an interest in lucid dreaming
Interventions Galantamine Mnemonic Induction of Lucid Dreams technique
Dose 0, 4, and 8 mg
Duration 3 consecutive nights
Topics Lucid dreaming Dreaming
Keywords Galantamine Placebo Recall Crossover study Consciousness Cognitive psychology Traditional medicine
Citations 59
Key findings Galantamine increases the frequency of lucid dreams in a dose-related manner, with 4 mg and 8 mg doses significantly outperforming placebo.

Abstract

Lucid dreaming is a remarkable state of consciousness in which one is aware of the fact that one is dreaming while continuing to dream. Based on the strong relationship between physiological activation during rapid eye-movement sleep and lucid dreaming, our pilot research investigated whether enhancing cortical activation via acetylcholinesterease inhibition (AChEI) would increase the frequency of lucid dreams and found AChEI to be a promising method for lucid dream induction. In the current study we sought to quantify the size and reliability of the effect of AChEI on lucid dreaming, dream recall and dream content as well as to test the effectiveness of an integrated lucid dream induction protocol which combined cholinergic stimulation with other methods for lucid dream induction. Participants (N = 121) with high dream recall and an interest in lucid dreaming were randomly assigned counterbalanced orders of 3 doses of galantamine (0, 4 and 8 mg). On 3 consecutive nights, they awoke approximately 4.5 hours after lights out, recalled a dream, ingested the capsules and stayed out of bed for at least 30 minutes. Participants then returned to bed and practiced the Mnemonic Induction of Lucid Dreams technique while returning to sleep. The percentage of participants who reported a lucid dream was significantly increased for both 4 mg (27%, odds ratio = 2.29) and 8 mg doses (42%, odds ratio = 4.46) compared to the active placebo procedure (14%). Galantamine also significantly increased dream recall, sensory vividness and complexity (p<0.05). Dream recall, cognitive clarity, control, positive emotion, vividness and self-reflection were increased during lucid compared to non-lucid dreams (p<0.0001). These results show that galantamine increases the frequency of lucid dreams in a dose-related manner. Furthermore, the integrated method of taking galantamine in the last third of the night with at least 30 minutes of sleep interruption and with an appropriately focused mental set is one of the most effective methods for inducing lucid dreams available today.

Comparable studies

Other randomized controlled trials on lucid dreaming, most cited first.

Study Year Design Participants
Lucid Dreaming Treatment for Nightmares: A Pilot Study Chronic nightmare sufferers 2006 Randomized controlled trial n = 23
Testing the involvement of the prefrontal cortex in lucid dreaming: A tDCS study Participants spending three consecutive nights in a sleep laboratory 2013 Randomized controlled trial n = 19
Effectiveness of motor practice in lucid dreams: a comparison with physical and mental practice Adults who completed an online experiment 2015 Randomized controlled trial n = 68
Studies with lucid dreaming as add-on therapy to Gestalt therapy Adults with nightmares (ICD-10: F51.5) at least twice a week 2015 Randomized controlled trial n = 32
Increased lucid dream frequency in long-term meditators but not following MBSR training. Long-term meditators and meditation-naïve individuals 2019 Cross-sectional study and blinded randomized controlled trial

Citations in the library

Explore topics